SGEN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 des 2023 @ 22:00):

Stats
Dagens volum	19.39M
Gjennomsnittsvolum	1.63M
Markedsverdi	43.15B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.19
ATR14	$1.424 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Baker Bros. Advisors Lp	Sell	42 977 301	Common Stock
2023-12-14	Baker Bros. Advisors Lp	Sell	8 750	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 44 783 214

Volum Korrelasjon

Lang: 0.24 (neutral)

Kort: 0.00 (neutral)

Signal:(82.918) Neutral

Seattle Genetics Inc Korrelasjon

10 Mest positive korrelasjoner
MLTX	0.927
BLPH	0.927
LGST	0.924
INTA	0.918
SJ	0.917
MOTNU	0.911
MORF	0.907
SVFC	0.907
PESI	0.903
DSEY	0.903

10 Mest negative korrelasjoner
ESSA	-0.937
BSRR	-0.937
FNCB	-0.936
SIRI	-0.934
APEI	-0.921
BRKL	-0.92
BLFY	-0.919
ONEM	-0.916
FLIC	-0.913
BCOW	-0.912

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Seattle Genetics Inc Korrelasjon - Valuta/Råvare

-0.75
( moderate negative )

-0.80
( strong negative )

0.25
( neutral )

-0.81
( strong negative )

-0.03
( neutral )

0.78
( moderate )

Seattle Genetics Inc Økonomi

Annual	2022
Omsetning:	$1.96B
Bruttogevinst:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2022
Omsetning:	$1.96B
Bruttogevinst:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2021
Omsetning:	$1.57B
Bruttogevinst:	$1.26B (80.21 %)
EPS:	$-3.70

FY	2020
Omsetning:	$2.18B
Bruttogevinst:	$1.96B (89.99 %)
EPS:	$3.51

Financial Reports:

No articles found.

Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.